Publications by authors named "Lynn S Zur Bonsen"
Background: Adalimumab, an anti-TNF-α biologic agent, has emerged as a principal treatment option for patients with non-infectious uveitis. The influence of adalimumab anti-drug antibodies (AAA) on the efficacy of adalimumab therapy is not yet fully understood. We aim to understand their clinical implications in the context of therapeutic drug monitoring and the factors contributing to the formation of these antibodies.
View Article and Find Full Text PDFLong-term effects of tocilizumab on retinal and choroidal inflammation in Birdshot uveitis.
J Ophthalmic Inflamm Infect
November 2024
Article Synopsis
- Tocilizumab (TCZ) is a drug used for rheumatic diseases that has shown promise in treating refractory non-infectious uveitis (NIU), particularly in Birdshot NIU, and this study examined its long-term effects.
- Eight patients were monitored over an average of 33 months using various imaging techniques to assess retinal and choroidal inflammation, with significant improvements noted in retinal inflammation and central retinal thickness (CRT) after six months.
- While TCZ effectively reduced retinal vasculitis and improved CRT, it was less effective for choroidal inflammation, indicating a need for further research to optimize TCZ treatment in NIU patients.
Ocular involvement is present in up to 79% of sarcoid patients. Uveitis is the main ocular manifestation and presents as a chronic intraocular inflammatory condition with potentially detrimental effects on visual acuity and quality of life. This retrospective study was conducted to explore the incidence and characteristics of ocular sarcoidosis in a single tertiary ophthalmology center.
View Article and Find Full Text PDFBackground: Several microRNAs (miRs) have been described as potential biomarkers in liquid biopsies and in the context of allergic asthma, while therapeutic effects on the airway expression of miRs remain elusive. In this study, we investigated epigenetic miR-associated mechanisms in the sputum of grass pollen-allergic patients with and without allergen-specific immunotherapy (AIT).
Methods: Induced sputum samples of healthy controls (HC), AIT-treated and -untreated grass pollen-allergic rhinitis patients with (AA) and without asthma (AR) were profiled using miR microarray and whole-transcriptome microarray analysis of the same samples.